Compare DexCom, Inc. (DXCM) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Wolfspeed Inc — how do they compare? DexCom, Inc. trades at $83.89 (market cap $31.86B), while Wolfspeed Inc trades at $30.31 (market cap $1.64B). The key difference: DexCom, Inc. is far larger — about 19.4× Wolfspeed Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Wolfspeed Inc for 19 Days on average.
| DXCM | WOLF | |
|---|---|---|
Market Cap | $31.86B | $1.64B |
Volume | 3,607,070 | 22,772,687 |
Sector | Health | Technology |
52-Week High | $92.34 | $73.68 |
52-Week Low | $54.84 | $14.80 |
Typical Hold Time | 62 Days | 19 Days |
Enterprise Value | $31.32B | $2.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Wolfspeed (WOLF) trades at $31.23, down 0.45% on the day, with a bullish technical signal driven by moving averages. The company reported a significant net loss of -$1.61B in 2025, with negative gross and net profit margins, though 2026 projections show potential for a small profit. Recent news highlights expansion of its 200mm silicon carbide portfolio, positioning it in the growing AI infrastructure sector.
The outlook is mixed; analyst consensus is a Buy with a $54.32 price target, suggesting substantial upside, but high execution risk remains due to persistent losses and ongoing legal investigations. Revenue growth and achieving profitability are critical for stock performance, with the transition to 800-volt AI data centers being a potential catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
